The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus
1997/05/01 by Dafna D. Gladman, Murray B. Urowitz, Charles H. Goldsmith +16 · 26 citations
Medicine · #Systemic Lupus Erythematosus Research #Rheumatoid Arthritis Research and Therapies #Systemic Sclerosis and Related Diseases
paper · doi:10.1002/art.1780400506
Abstract
OBJECTIVE: To test the reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in the assessment of patients with SLE. METHODS: Ten patients with SLE, representing a spectrum of damage and activity, were included. Each patient was examined by 6 of 10 physicians from 5 countries, representing 10 lupus clinics. The SLICC/ACR Damage Index was used to assess accumulated damage, and the SLEDAI was used to assess disease activity. The order of the patients and physicians was randomized according to a Youden square design. RESULTS: The SLICC/ACR Damage Index detected differences among patients (P < 0.001). There was no detectable observer difference (P = 0.933), and there was no order effect (P = 0.261). Similar results were obtained with the SLEDAI. There was concordance in the SLICC/ACR Damage Index among observers, despite a wide spectrum of disease activity detected by the SLEDAI. CONCLUSION: Physicians from different centers are able to assess patients with SLE in a reproducible way, using the SLEDAI to assess disease activity and the SLICC/ACR Damage Index to assess accumulated damage.
Citations
Cited by
- Diverse antiphospholipid syndromes and beyond: A multicenter comprehensive analysis from the Egyptian College of Rheumatology
- Role of resistin as a marker of inflammation in systemic lupus erythematosus. [europepmc]
- Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). [europepmc]
- Understanding the epidemiology and progression of systemic lupus erythematosus. [europepmc]
- Prednisone, lupus activity, and permanent organ damage. [europepmc]
- Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. [europepmc]
- Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. [europepmc]
- Diffusion tensor imaging in neuropsychiatric systemic lupus erythematosus. [europepmc]
- Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. [europepmc]
- Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. [europepmc]
- Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). [europepmc]
- Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. [europepmc]
- Circulating microRNA expression profiles associated with systemic lupus erythematosus. [europepmc]
- Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. [europepmc]
- Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. [europepmc]
- Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. [europepmc]
- Immunomodulators in SLE: Clinical evidence and immunologic actions. [europepmc]
- Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. [europepmc]
- Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. [europepmc]
- Myocarditis in systemic lupus erythematosus diagnosed by 18 F-fluorodeoxyglucose positron emission tomography. [europepmc]
- Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. [europepmc]
- Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. [europepmc]
- Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. [europepmc]
- Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. [europepmc]
- The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. [europepmc]
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. [europepmc]
Related